BlossomHill Therapeutics Reports Q3 2026 Results, $224.9 Million in Cash

BlossomHill Therapeutics reported a third-quarter 2026 net loss of $24.0 million, compared with a $16.0 million loss a year earlier. Research and development expenses rose to $21.9 million, while cash and cash equivalents totaled $224.9 million at September 30, 2026. The company said its cash is ex…